Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (6020)	11/20/2004 7:44:24 AM
From: quidditch	Respond to of 10345

Harold, <<And in Elan's case, I think safety and efficacy data....>> That is a big difference here: all we know is that all secondary endpoints were met. When (if) the one year data is released "upon approval" (as ELN has said)and if clinical results as to secondary endpoints are very persuasive (such as lesion clearance), and indicate that there will be significant impact on disease progression in the two year data, the situation could be very different from OSIP. quid

To: Harold Engstrom who wrote (6020)	11/20/2004 10:11:40 AM
From: rkrw	Read Replies (1) \| Respond to of 10345

Tarceva label is very good. When you see hundreds of elan yahoo posts predicting a huge run immediately after approval (which is expected), that just begs for a sell on the news :-)